DeepMed Research

Doxazosin

Generic Name: Doxazosin

Brand Names: Cardura

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₅N_₅O_₅

CAS Number: 74191-85-8

Unique Ingredient Identifier: NW1291F1W8

Background: Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990.

Indication: Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension. Off-label uses of doxazosin include the treatment of pediatric hypertension and the treatment of ureteric calculi.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Hypertension, Ureteric calculus

Clinical Trials

Doxazosin an a1 Antagonist for Alcohol Dependence

Phase 2

Completed

Conditions: Anxiety
Alcohol Dependence

Interventions: Drug: Placebo
Drug: Doxazosin

First Posted Date: 2011-09-20

Last Posted Date: 2015-07-22

Lead Sponsor: Brown University

Target Recruit Count: 48

Registration Number: NCT01437046

Locations: 🇺🇸
Brown University Center for Alcohol and Addiction Studies, Providence, Rhode Island, United States

Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Doxazosin 4 mg Japanese marketed IR tablet
Drug: Doxazosin 4 mg ODT with water
Drug: Doxazosin 4 mg ODT without water

First Posted Date: 2011-07-08

Last Posted Date: 2021-01-29

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 24

Registration Number: NCT01389609

Locations: 🇯🇵
Pfizer Investigational Site, Shinjuku-ku, Tokyo, Japan

Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)

Phase 1

Completed

Conditions: Substance-Related Disorders
Mood Disorder
Amphetamine-Related Disorders

Interventions: Drug: 3,4-Methylenedioxymethamphetamine
Drug: Doxazosin
Drug: placebo

First Posted Date: 2011-06-30

Last Posted Date: 2018-12-11

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 16

Registration Number: NCT01386177

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

Phenoxybenzamine Versus Doxazosin in PCC Patients

Phase 4

Completed

Conditions: Pheochromocytoma

Interventions: Drug: Phenoxybenzamine
Drug: Doxazosin

First Posted Date: 2011-06-23

Last Posted Date: 2018-01-31

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 134

Registration Number: NCT01379898

Locations: 🇳🇱
Department of Endocrinology, University Medical Center Groningen, Groningen, Netherlands

Doxazosin for Psychostimulant Dependence

Phase 1

Completed

Conditions: Methamphetamine or Cocaine Dependence

Interventions: Drug: Doxazosin extended release

First Posted Date: 2011-06-13

Last Posted Date: 2015-07-27

Lead Sponsor: University of Arkansas

Target Recruit Count: 22

Registration Number: NCT01371851

Locations: 🇺🇸
UAMS Psychiatric Research Institute, Little Rock, Arkansas, United States

Pharmacogenetics of Doxazosin for Cocaine Dependence

Phase 2

Completed

Conditions: Cocaine Dependence

Interventions: Drug: Doxazosin
Drug: Placebo

First Posted Date: 2010-06-16

Last Posted Date: 2019-07-22

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 96

Registration Number: NCT01145183

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

Phase 1

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Tamsulosin and avanafil
Drug: Doxazosin and avanafil

First Posted Date: 2010-04-08

Last Posted Date: 2011-01-07

Lead Sponsor: VIVUS LLC

Target Recruit Count: 48

Registration Number: NCT01100021

Locations: 🇺🇸
MDS Pharma Services Inc.,, Tempe, Arizona, United States

The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine

Phase 1

Completed

Conditions: Cocaine Addiction
Cocaine Abuse
Cocaine Dependence
Substance Abuse

Interventions: Drug: Placebo
Drug: Doxazosin

First Posted Date: 2010-02-04

Last Posted Date: 2012-07-27

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 13

Registration Number: NCT01062945

Locations: 🇺🇸
Michael Debakey VA Medical Center, Houston, Texas, United States

A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Doxazosin mesylate GITS

First Posted Date: 2009-10-29

Last Posted Date: 2021-01-28

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 989

Registration Number: NCT01003886

Locations: 🇵🇭
Pfizer Investigational Site, West Fairview, Quezon City, Philippines

Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia
Overactive Bladder

Interventions: Drug: doxazosin plus tolterodine SR

First Posted Date: 2009-06-17

Last Posted Date: 2019-12-02

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 83

Registration Number: NCT00922506

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy